Epson Showcasing Latest Printer Technology and Hosting “Epson Print Academy” In-Booth Demonstrations at PhotoPlus Expo

Logo

Epson Showcasing Latest Printer Technology and Hosting “Epson Print Academy” In-Booth Demonstrations at PhotoPlus Expo

PR Newswire

LONG BEACH, Calif., Oct. 19, 2017 /PRNewswire/ – MEDIA ALERT:

Epson America, Inc.


Who: 

Epson will be participating in the upcoming PhotoPlus Expo show in New York City to showcase its latest advancements in imaging technology for the photographic community in booth #707.


What: 

During the show, Epson will host “Epson Print Academy,” a series of presentations with professional photographers and printing experts on digital printing workflows, including demonstrations on how to optimize files for exhibition quality printing. In addition, presenters will be printing with the new SureColor® P5000 professional 17-inch inkjet printer.

Additional information on specific events and participating products follow.


Epson
Print Academy

Epson will be hosting a series of 30-minute presentations from some of the industry’s top photographic printing experts. Presentations will demonstrate the process of optimizing files to create the highest quality prints.


Epson SureColor P5000 Demonstration:

Epson will be demonstrating the award-winning SureColor P5000 printer. Attendees are invited to bring high-resolution files to Epson’s booth to print on the SureColor P5000 to experience its exceptional output first-hand. Leveraging the advanced Epson PrecisionCore® TFP® printhead and 10-color Epson UltraChrome® HDX® pigment ink set with new Orange and Green ink, the SureColor P5000 delivers output with a wider contrast ratio and optically clearer, sharper images. A refined printer design includes improved dust and static control for reduced nozzle maintenance and enhanced performance and reliability.


Epson Print Layout Station:

Epson Print Layout is designed to simplify complex print and color management workflows for photographers. This software incorporates an intuitive linear workflow design to provide easy printer selection, layout and color management settings, in addition to providing a live Advanced Black-and-White Mode1 output preview. Compatible with Epson SureColor P-Series printers1, Epson Print Layout is the ideal solution for photography enthusiasts and professional photographers looking to create high-quality photos. Epson will have a dedicated station where attendees can bring personal high-resolution files and use Epson Print Layout to output their photographs on the SureColor P5000.


Epson Legacy Papers:

Legacy Platine, Legacy Fibre, Legacy Baryta, Legacy Etching – represent the art of papermaking at its finest. Designed in collaboration with many of the world’s greatest artists and revered European papermakers and galleries, and developed specifically for those who intend to exhibit and sell their prints, both to art collectors and investors. Producing outstanding black density and color fidelity, along with exceptional archival properties, the Epson Legacy Papers offer the properties required for high-end photographic fine art printing and collectible works of fine art. For additional information about Epson’s Legacy Papers, visit www.epson.com/legacypapers

When: PhotoPlus Expo runs from Oct. 26-28, 2017 and the exhibit hall is open from 10 a.m. to 5 p.m. on Thursday and Friday and 10 a.m. to 4 p.m. on Saturday. Following is the list of “Epson Print Academy” sessions that will be held at Epson’s booth:


“Epson Print Academy” Presentation Schedule


Thursday, Oct. 26


Friday, Oct. 27


Saturday, Oct. 28

11-11:30 a.m.

Julianne Kost

11-11:30 a.m.

Julianne Kost

11-11:30 a.m.

Matt Kloskowski

Noon-12:30 p.m.

Mac Holbert

Noon-12:30 p.m.

Mac Holbert

Noon-12:30 p.m.

Vincent Versace

1-1:30 p.m.

John Paul Caponigro

1-1:30 p.m.

John Paul Caponigro

1-1:30 p.m.

Matt Kloskowski

2-2:30 p.m.

Mac Holbert

2-2:30 p.m.

Matt Kloskowski

2-2:30 p.m.

Vincent Versace

3-3:30 p.m.

John Paul Caponigro

3-3:30 p.m.

Vincent Versace

4-4:30 p.m.

Vincent Versace

Where: Javits Convention Center, New York City; Epson Booth #707

For additional information about Epson professional imaging solutions visit www.proimaging.epson.com

About Epson
Epson is a global technology leader dedicated to connecting people, things and information with its original efficient, compact and precision technologies. With a lineup that ranges from inkjet printers and digital printing systems to 3LCD projectors, smart glasses, sensing systems and industrial robots, the company is focused on driving innovations and exceeding customer expectations in inkjet, visual communications, wearables and robotics.

Led by the Japan-based Seiko Epson Corporation, the Epson Group comprises more than 72,000 employees in 88 companies around the world, and is proud of its contributions to the communities in which it operates and its ongoing efforts to reduce environmental impacts.

Epson America, Inc., based in Long Beach, Calif., is Epson’s regional headquarters for the U.S., Canada, and Latin America. To learn more about Epson, please visit: epson.com. You may also connect with Epson America on Facebook (facebook.com/Epson), Twitter (twitter.com/EpsonAmerica), YouTube (youtube.com/EpsonAmerica), and Instagram (instagram.com/EpsonAmerica).

1 SureColor P10000 and P20000 not currently supported

Note: EPSON, SureColor, PrecisionCore, TFP, UltraChrome HDX are registered trademarks and EPSON Exceed Your Vision is a registered logomark of Seiko Epson Corporation. All other product brand names are trademarks and/or registered trademarks of their respective companies. Epson disclaims any and all rights in these marks. Copyright 2017 Epson America, Inc. CPD-53976 5/17

 

View original content with multimedia:http://www.prnewswire.com/news-releases/epson-showcasing-latest-printer-technology-and-hosting-epson-print-academy-in-booth-demonstrations-at-photoplus-expo-300539561.html

SOURCE Epson America, Inc.

MilliporeSigma Brings Customers Closer to Gene Therapy Product Commercialization

MilliporeSigma Brings Customers Closer to Gene Therapy Product Commercialization

Canada NewsWire

– Company’s Carlsbad manufacturing facility passes FDA and EMA inspections

– Underscores capabilities as commercial manufacturer of viral and gene therapy products

– Highlights position as leading contract manufacturing organization (CMO) for production of next-generation gene therapies

BURLINGTON, Mass., Oct. 19, 2017 /CNW/ — MilliporeSigma today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S. Food & Drug Administration (FDA) Pre-License inspection and a European Medicines Agency (EMA) Marketing Authorization Application inspection.

“The successful FDA and EMA inspections of our Carlsbad manufacturing facility mark an important milestone for MilliporeSigma and our customers who are manufacturing exciting new treatments for cancer and many other diseases,” said Udit Batra, CEO, MilliporeSigma. “As one of the first CMOs in the industry to complete pre-licensure inspections for this class of therapies, this achievement underscores our commitment to bring our customers one step closer to commercialization of novel therapies.”

These inspections will enable one of MilliporeSigma’s key customers to launch its novel gene therapy in both the U.S. and in Europe, which is currently under review by both the FDA and EMA. The inspections were significant milestones in the approval process to obtain the licenses necessary to manufacture the gene therapy as a commercial product.

This key benchmark underscores MilliporeSigma’s continued investment in viral and gene therapies from clinical to commercial scale. MilliporeSigma has close to three decades of experience in gene therapy, and its Carlsbad site has been involved in the gene therapy area since 1997, near the time clinical trials for gene therapy began.

The Carlsbad facility provides contract development and manufacturing services that can contribute to a more efficient delivery of these lifesaving therapies to market. The business serves many leading developers of viral and gene therapy products globally.

The company’s Carlsbad facility underwent a major expansion in 2016, and is now nearly double its former production capacity. The upgraded facility grew from 44,000 square feet to 65,000 square feet and now includes 16 modular viral bulk manufacturing cleanroom suites with single-use equipment and two fill/finish suites for gene therapy, viral vaccine and immunotherapy products.

MilliporeSigma also offers viral and gene therapy manufacturing capacity in Glasgow, Scotland, has cell-banking services in Rockville, Maryland, and offers BioReliance® biosafety testing globally for both clinical and commercial stage gene therapy products.

Gene therapy involves the delivery of genetic material into patient cells to produce a therapeutic effect such as correction of a mutated gene or retargeting of an immune cell to fight cancer. Diseases such as hemophilia and cancer are being investigated using this technique where a single dose may cure the disease.

MilliporeSigma recognizes the potential benefits of conducting properly defined research with genome editing because of the breakthrough therapeutic potential. Therefore, research with genome editing is allowed with careful consideration of ethical and legal standards. MilliporeSigma’s parent company has established a Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has five businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials – and generated sales of €15 billion in 2016. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

View original content with multimedia:http://www.prnewswire.com/news-releases/milliporesigma-brings-customers-closer-to-gene-therapy-product-commercialization-300539095.html

SOURCE MilliporeSigma

View original content with multimedia: http://www.newswire.ca/en/releases/archive/October2017/19/c3697.html

Benson Hill Biosystems Launches the First Fully Enabling Genome Editing System for Crop Improvement

Logo

Benson Hill Biosystems Launches the First Fully Enabling Genome Editing System for Crop Improvement

System Available to Partners to Leverage Natural Plant Genetic Diversity

PR Newswire

LONDON, Oct. 19, 2017 /PRNewswire/ – Benson Hill Biosystems, an agricultural technology company dedicated to unlocking the natural genetic potential of plants, today announced at the Future Food-Tech Conference the commercial launch of Edit, powered by CropOS™, the first complete genome editing system made accessible to partners for the development of improved crops.

Benson Hill Biosystems Launches the First Fully Enabling Genome Editing System for Crop Improvement

“There is an urgent need to redefine the model of crop innovation and drive greater improvement in the health and resiliency of our food system,” said Matt Crisp, CEO and co-founder of Benson Hill Biosystems. “Genome editing can help level the playing field, empowering a robust community of innovators to modernize our food system with simpler ingredients and production methods – plant-based proteins and ancient grains, natural disease resistance, and other targets that create more choice for both farmers and consumers.”

A Uniquely Comprehensive Genome Editing System to Unlock Nature’s Diversity

The Edit system combines the analytical power of Benson Hill’s CropOS™ computational platform with a robust portfolio of novel genome editing nucleases to create the first comprehensive genome editing system. Edit is designed to optimize plant characteristics such as flavor profiles, nutrient-density, and environmental sustainability with greater speed and precision than previously possible.

“The combination of a machine learning-based prediction engine with best-in-class genome editing chemistry affords users of CropOS an unprecedented opportunity to innovate in a rapidly evolving food system,” said Dr. Paul Skroch, Vice President of Data Science and Platform Engineering for Benson Hill. ”The parallel advancements in AI, big data, and the cloud are converging to address the most substantial challenge for an effective genome editing system: efficiently identifying specific sequence locations in the plant genome to edit. Using an integrated platform, we are accelerating the plant breeding process and more fully leveraging natural genetic diversity as a differentiator in product development.”

Empowering Innovation to Improve our Food System

CropOS is a community platform that empowers companies of any size throughout the food and agriculture value chain to access the most advanced tools in seed innovation without major infrastructure costs or distraction from their core business. Benson Hill’s Edit system combines insights from CropOS with a diverse portfolio of novel CRISPR 3.0 nucleases shown to demonstrate broad application and a smaller size for easier delivery. 

“Few industries can have as much impact to reduce CO2 levels as food production,” said Mark Cupta, Principal at Prelude Ventures, which co-led Benson Hill’s $25M Series B round of financing. ”From photosynthesis efficiency to soil health, Benson Hill empowers organizations to reduce the footprint and increase the resiliency of agricultural supply chains, an approach that fully aligns with our mission to promote innovations that have a positive impact on climate.”

Click here to learn more about the technical benefits and business applications of the Edit system.

About Benson Hill Biosystems

Benson Hill Biosystems is an agricultural technology company that unlocks the global genetic potential of plants to enhance the sustainability of food, feed, fiber and fuel production. Benson Hill and our partners harness natural and novel genetic variation through breeding, trait development and genome editing to develop products that accelerate crop improvement. More information can be found online at www.bensonhillbio.com. Follow us on Twitter at @BensonHillBio.

 

Benson Hill Biosystems, Inc. (PRNewsfoto/Benson Hill Biosystems)

View original content with multimedia:http://www.prnewswire.com/news-releases/benson-hill-biosystems-launches-the-first-fully-enabling-genome-editing-system-for-crop-improvement-300539589.html

SOURCE Benson Hill Biosystems